INN-202 is currently the only drug candidate entering into Phase 3 trials. Larazotide is shown to be effective with hundreds of patients. The company has drug candidates also for NASH, Crohn's, and ulcerative colitis in addition to more than 150 patents. They recently hired somebody with successful Phase 3 experience on other drugs.
The recent analyst day was great, in my opinion, with strong product pipeline which should be followed by strong delivery. Guidance is up and most likely conservative going into next month's earnings call. Short term headwinds with regards to overbought status should dissipate soon as Tandem is far from being overbought. It has a strong chance of becoming a market...
Great momentum so far with this stock. Recent insider buys as well as positive analyst commentary. Upon FDA approval, Olinvo can become a game changer. Fingers crossed for future upside.
Recent analyst downgrade was no less than pure manipulation to create new long term holders, most likely institutional holders as we are approaching the Sep 25th conference. Most analysts are still bullish, and there are several catalysts ahead through 2020 like t:sport, Control-IQ, sales on Basal-IQ, international expansion, and possible UHC coverage. Tandem also...
It has tested the green support line three times since it went IPO. Last 7 trading sessions were all red with below-average volume. If the stock decides to move up from this level, it will need to break the $32 zone as a lot of buy/sell activity took place there. Today, the company raises more funds for its Sports venture, which is a good sign as investors believe...
